Compare Novo Nordisk A/S (NVO) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Victoria's Secret & Co — how do they compare? Novo Nordisk A/S trades at $46.49 (market cap $207.85B), while Victoria's Secret & Co trades at $94.16 (market cap $7.48B). The key difference: Novo Nordisk A/S is far larger — about 27.8× Victoria's Secret & Co's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| NVO | VSXY | |
|---|---|---|
Market Cap | $207.85B | $7.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $99.97 |
52-Week Low | $35.29 | $21.34 |
Enterprise Value | $222.55B | $10.13B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Victoria's Secret (VSXY) trades at $92.97, down 7.0% on the day but maintains strong technical momentum with bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive cash flow projections for 2026. Recent news highlights international expansion success, particularly in China, and data-driven marketing initiatives driving growth.
The stock presents a balanced opportunity with analyst consensus favoring Buy ratings (55.6%) and a $91 price target near current levels. Key risks include competitive pressures in apparel retail and margin volatility, while catalysts include continued international growth and potential earnings surprises in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
